SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-061473
Filing Date
2024-03-07
Accepted
2024-03-07 07:08:00
Documents
16
Period of Report
2024-03-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d803910d8k.htm   iXBRL 8-K 25314
2 EX-99.1 d803910dex991.htm EX-99.1 62184
6 GRAPHIC g803910g0307041351216.jpg GRAPHIC 2626
  Complete submission text file 0001193125-24-061473.txt   227360

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nmra-20240307.xsd EX-101.SCH 2855
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nmra-20240307_lab.xml EX-101.LAB 18736
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nmra-20240307_pre.xml EX-101.PRE 11710
17 EXTRACTED XBRL INSTANCE DOCUMENT d803910d8k_htm.xml XML 3769
Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

IRS No.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41802 | Film No.: 24728136
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)